These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 29786888)

  • 41. Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies.
    Mullins SR; Vasilakos JP; Deschler K; Grigsby I; Gillis P; John J; Elder MJ; Swales J; Timosenko E; Cooper Z; Dovedi SJ; Leishman AJ; Luheshi N; Elvecrog J; Tilahun A; Goodwin R; Herbst R; Tomai MA; Wilkinson RW
    J Immunother Cancer; 2019 Sep; 7(1):244. PubMed ID: 31511088
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
    Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
    J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Bioadhesive injectable hydrogel with phenolic carbon quantum dot supported Pd single atom nanozymes as a localized immunomodulation niche for cancer catalytic immunotherapy.
    He H; Fei Z; Guo T; Hou Y; Li D; Wang K; Ren F; Fan K; Zhou D; Xie C; Wang C; Lu X
    Biomaterials; 2022 Jan; 280():121272. PubMed ID: 34864428
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches.
    Song D; Powles T; Shi L; Zhang L; Ingersoll MA; Lu YJ
    J Pathol; 2019 Oct; 249(2):151-165. PubMed ID: 31102277
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Designing Hydrogels for On-Demand Therapy.
    Oliva N; Conde J; Wang K; Artzi N
    Acc Chem Res; 2017 Apr; 50(4):669-679. PubMed ID: 28301139
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells.
    Foy SP; Mandl SJ; dela Cruz T; Cote JJ; Gordon EJ; Trent E; Delcayre A; Breitmeyer J; Franzusoff A; Rountree RB
    Cancer Immunol Immunother; 2016 May; 65(5):537-49. PubMed ID: 26961085
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
    Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
    Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Combined Radiation Therapy and Immune Checkpoint Blockade Therapy for Breast Cancer.
    Hu ZI; Ho AY; McArthur HL
    Int J Radiat Oncol Biol Phys; 2017 Sep; 99(1):153-164. PubMed ID: 28816141
    [TBL] [Abstract][Full Text] [Related]  

  • 49. An injectable superior depot of Telratolimod inhibits post-surgical tumor recurrence and distant metastases.
    Liu Y; Li C; Xia H; Bi J; Guan R; Du X; Zhang H; He Z; Wang Y; Liu H
    Acta Biomater; 2022 Mar; 141():132-139. PubMed ID: 35032721
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Nanoenabled Modulation of Acidic Tumor Microenvironment Reverses Anergy of Infiltrating T Cells and Potentiates Anti-PD-1 Therapy.
    Zhang YX; Zhao YY; Shen J; Sun X; Liu Y; Liu H; Wang Y; Wang J
    Nano Lett; 2019 May; 19(5):2774-2783. PubMed ID: 30943039
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Immunosuppressive Myeloid Cells' Blockade in the Glioma Microenvironment Enhances the Efficacy of Immune-Stimulatory Gene Therapy.
    Kamran N; Kadiyala P; Saxena M; Candolfi M; Li Y; Moreno-Ayala MA; Raja N; Shah D; Lowenstein PR; Castro MG
    Mol Ther; 2017 Jan; 25(1):232-248. PubMed ID: 28129117
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immunotherapy for advanced melanoma: Current knowledge and future directions.
    Nakamura K; Okuyama R
    J Dermatol Sci; 2016 Aug; 83(2):87-94. PubMed ID: 27302423
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors.
    Holmgaard RB; Zamarin D; Lesokhin A; Merghoub T; Wolchok JD
    EBioMedicine; 2016 Apr; 6():50-58. PubMed ID: 27211548
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immunotherapy of Lymphoma and Myeloma: Facts and Hopes.
    Pianko MJ; Moskowitz AJ; Lesokhin AM
    Clin Cancer Res; 2018 Mar; 24(5):1002-1010. PubMed ID: 28899972
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immunotherapy in breast cancer: An overview of modern checkpoint blockade strategies and vaccines.
    Sanchez K; Page D; McArthur HL
    Curr Probl Cancer; 2016; 40(2-4):151-162. PubMed ID: 27855963
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies.
    Philips GK; Atkins M
    Int Immunol; 2015 Jan; 27(1):39-46. PubMed ID: 25323844
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Oncolytic Newcastle disease virus expressing a checkpoint inhibitor as a radioenhancing agent for murine melanoma.
    Vijayakumar G; Palese P; Goff PH
    EBioMedicine; 2019 Nov; 49():96-105. PubMed ID: 31676387
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Indoleamine Dioxygenase Inhibitors: Clinical Rationale and Current Development.
    Zhu MMT; Dancsok AR; Nielsen TO
    Curr Oncol Rep; 2019 Jan; 21(1):2. PubMed ID: 30659394
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Low-dose X-ray radiotherapy-radiodynamic therapy via nanoscale metal-organic frameworks enhances checkpoint blockade immunotherapy.
    Lu K; He C; Guo N; Chan C; Ni K; Lan G; Tang H; Pelizzari C; Fu YX; Spiotto MT; Weichselbaum RR; Lin W
    Nat Biomed Eng; 2018 Aug; 2(8):600-610. PubMed ID: 31015630
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Indoleamine 2,3-Dioxygenase (IDO) Inhibition as a Strategy to Augment Cancer Immunotherapy.
    Yentz S; Smith D
    BioDrugs; 2018 Aug; 32(4):311-317. PubMed ID: 29980987
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.